Carla Kim | Genetics

Carla Kim, Ph.D.

Professor of Genetics

Phone:

617/919-4644

Fax:

617/730-0222

carla.kim@childrens.harvard.edu

Tabs

Bio

The broad interest of the Kim Lab is to characterize the biology of stem cells in normal lung and lung cancer. Numerous lung diseases such as cystic fibrosis or chronic obstructive pulmonary disease involve injured or depleted bronchiolar or alveolar epithelium. Bronchiolar and alveolar cells are also affected in adenocarcinoma, the most common form of lung cancer. It is likely that lung stem cells are critically affected in patients with these devastating diseases. Our long-term goal is to elucidate the role of stem cells in lung homeostasis as a prerequisite to the development of therapeutic strategies that can be used to prevent or attenuate lung disease.

Please see our website for more information:
http://kim.tchlab.org/

Publications

E-cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma.

Carla Kim, Ph.D.

American journal of respiratory cell and molecular biology, February 15, 2018

Sinkevicius KW, Bellaria KJ, Barrios J, Pessina P, Gupta M, Brainson CF, Bronson RT, Kim CF

Link to abstract on PubMed

Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury.

Carla Kim, Ph.D.

Stem cell research & therapy, November 10, 2017

Zhu D, Tan J, Maleken AS, Muljadi R, Chan ST, Lau SN, Elgass K, Leaw B, Mockler J, Chambers D, Leeman KT, Kim CF, Wallace EM, Lim R

Link to abstract on PubMed

Anatomically and Functionally Distinct Lung Mesenchymal Populations Marked by Lgr5 and Lgr6.

Carla Kim, Ph.D.

Cell, September 7, 2017

Lee JH, Tammela T, Hofree M, Choi J, Marjanovic ND, Han S, Canner D, Wu K, Paschini M, Bhang DH, Jacks T, Regev A, Kim CF

Link to abstract on PubMed

Intersections of lung progenitor cells, lung disease and lung cancer.

Carla Kim, Ph.D.

European respiratory review : an official journal of the European Respiratory Society, June 28, 2017

Kim CF

Link to abstract on PubMed

Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Carla Kim, Ph.D.

Nature communications, June 9, 2017

Zhang H, Brainson CF, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Alan...

Link to abstract on PubMed

Don't Stop Re-healin'! Cancer as an Ongoing Stem Cell Affair.

Carla Kim, Ph.D.

Cell, May 4, 2017

Rowbotham SP, Kim CF

Link to abstract on PubMed

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Carla Kim, Ph.D.

Nature communications, April 7, 2017

Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ,...

Link to abstract on PubMed

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Carla Kim, Ph.D.

Cancer discovery, June 16, 2016

Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF,...

Link to abstract on PubMed

Tracing the potential of lung progenitors.

Carla Kim, Ph.D.

Nature biotechnology, February 1, 2015

Mahoney JE, Kim CF

Link to abstract on PubMed

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

Carla Kim, Ph.D.

Nature, January 28, 2015

Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF

Link to abstract on PubMed

1
2
3
4
5
next ›
last »

Contact

Address: